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Overline: Stem Cells 
 
Abstract Commercial promotion of unsupported therapeutic uses of stem cells 
is a global problem that has proven extraordinarily resistant to regulatory efforts. We 
suggest a coordinated global-local approach focused on engagement, harmonization 
and enforcement is needed reduce the risks and harms associated with direct-to-
consumer marketing of unproven stem cell treatments.  
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The growth of the industry engaged in direct-to-consumer marketing of unproven 
stem cell interventions online has become impossible to ignore1, 2. Effective measures 
for regulating this sector both nationally and internationally are urgently needed. 
Despite the lack of compelling evidence from well-designed studies to support their 
efficacy3, or even in many cases of a plausible biological rationale, many providers 
aggressively promote the use of stem cells for a wide range of indications. Such 
practices first emerged in the peripheries of international biomedical research and 
development4, but providers have been making inroads in some leading global 
markets, including Japan5, Australia2, 6, and the United States1, 7. Public warnings by 
scientific and medical groups8, 9, government organizations10, and the media11 have 
not slowed the global expansion of an industry based on marketing of unproven stem 
cell treatments. The success of this industry has adverse implications for patients’ 
health and the integrity of healthcare markets, as well as potential repercussions for 
legitimate biomedical endeavors. It also provides an unsettling glimpse of what may 
lie ahead for other emerging biomedical technologies, such as mitochondrial 
replacement therapy and gene editing12. 
 
Efforts to ensure that stem cell-based interventions rest on a foundation of scientific 
evidence have not all been in vain. Authorities in Germany were successful in closing 
a private clinic that marketed stem cell treatments primarily to overseas patients, but 
only after several reports of serious adverse events, including the death of an infant13. 
The Chinese Ministry of Health has made significant strides in curtailing an industry 
in which hundreds of clinics promoted purported stem cell therapeutics over the 
internet14. More recently, the resolution of the Stamina Foundation controversy in 
Italy provides an excellent example of academic researchers and regulatory officials 
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successfully pushing back against a highly publicized provider of unproven stem cell 
treatments15. In this case, a private foundation aggressively promoted supposed 
therapeutic uses of mesenchymal stem cells, and gained national attention by rallying 
support from some media and advocacy groups around a narratives of patients’ rights 
and demands for accelerated testing and approval. Following a several year public 
debate and scientific review, the “Stamina method” was unanimously rejected as 
unworthy of further study by a Ministry of Health expert panel. This was an important 
victory in the fight to ensure that unsupported therapeutic claims about stem cell 
therapies do not go unchallenged. The Stamina Foundation case in particular provides 
important insights into how promoters of unproven stem cell treatments harness and 
manipulate popular sentiments and misconceptions, and how scientists and physicians 
can help to inform both media representations and public policy16. By mobilizing 
support from international scientific organizations and engaging with the public 
through traditional media and social media, scientists were able to exert a positive 
influence on national policies that initially appeared to be veering toward state 
support for pseudomedicine17.  
 
In this Perspective, we draw on the mounting body of literature describing the growth 
and characteristics of direct-to-consumer marketing of stem cell-based therapies1, 2, 18, 
19  to highlight a number of key features and challenges for broad-based efforts to 
regulate this industry. We also examine how past successes in countering the 
premature commercialization of stem cell-based therapies in medicine can inform 
coordinated responses to this phenomenon nationally and internationally. 
 
Defining the problem 
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The marketing of stem cells online takes place within a context of heightened direct-
to-consumer marketing activity in the health sector. DTC advertising of medical 
products and services reflects the increasingly commercialized and consumer-oriented 
nature of the health sector. The growth of the internet and social media have provided 
new outlets for the marketing of both licensed and unlicensed therapeutics and offer 
sellers the ability to reach worldwide audiences, highlighting the difficulties of 
enforcing national laws in a global marketplace20. Critics have cautioned that such 
unmediated forms of drug advertising may evade regulatory oversight and provide 
unreliable or incomplete information regarding risks, efficacy, and treatment 
alternatives21. 
 
Many professional organizations, including the largest international academic 
societies in cell therapy3 and stem cell research22, have adopted a staged approach to 
determining what constitutes sufficient evidence of efficacy to justify routine clinical 
uses of stem cells . These approaches hold that such decisions should typically be 
based on results from independent randomized, controlled clinical trials, a view 
broadly consistent with the norms of evidence-based medicine. Nevertheless, it is 
important to recognize that study designs and evidentiary standards continue to 
evolve, and there is a diversity of viewpoints on the nature and quality of evidence 
needed to support widespread clinical adoption. For this reason, there is inevitably a 
grey zone between the extremes of  strong scientific support and quackery23. 
Nonetheless, requiring new stem cell-based interventions to be carefully evaluated for 
safety and efficacy prior to entering widespread clinical use is consistent with best 
practices in biomedical research and development, for which there is substantial 
agreement across many jurisdictions. The steps involved in conventional clinical 
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translation of new therapies include: a compelling scientific rationale; well-defined 
and validated standards for ex vivo processing to achieve cellular product quality and 
potency; substantial evidence from rigorously designed independent clinical studies 
demonstrating safety and efficacy in the context of a specific medical indication; and 
the provision of information from such studies to inform clinical decision-making24.  
 Stem cell-based interventions are classified under diverse and potentially 
incompatible national regulatory frameworks. Many countries, including the United 
States, have defined a wide spectrum of treatments using human cell and tissue as 
medical products with the oversight of the U.S. Food and Drug Administration (FDA) 
in the United States, or equivalent national authority, such as the European Medicines 
Agency in the EU. Other countries, including Australia and Japan, allow physicians 
broad discretion in using autologous cells in the course of medical procedures25. In 
the majority of nations, however, clear rules governing the clinical use of stem cell-
based interventions are absent. Cell-based interventions may be categorized as 
‘products’, which are subject to oversight by national regulatory authorities, or as 
‘procedures’ conducted within the scope of medical practice. These distinct regulatory 
philosophies have direct implications for how stem cells can be advertised in different 
jurisdictions. Evidence standards in the context of commercial advertising, market 
authorization and standard of care often vary considerably, as do the enforcement 
options available to national regulators. 
 
Inflated messages 
Much of the coverage of stem cells in the popular press to date has been unjustifiably 
optimistic, both in terms of the potential clinical benefit and the time frame in which 
such treatments would reach routine clinical application26. This positive messaging is 
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leveraged by some providers to market unproven stem cell-based interventions. 
Indeed, the term ‘stem cell’ has been used broadly in promises of youth, rejuvenation 
and good health, as well as in the branding of cosmetics, dietary supplements, and 
sports products27. Such hyperbole carries with it not only an increased risk of 
exploitation of vulnerable families desperate for a cure, but also of significant damage 
to the health of those subjected to these unproven interventions. In the longer term, 
unfulfilled promises may bring regenerative medicine R&D into disrepute. 
  
In parallel to the hyping of the clinical utility of stem cells, providers of unproven 
stem cell interventions often display tokens of scientific legitimacy in their marketing 
messages (Table 1). Such tokens of scientific legitimacy include  publications in 
journals with weak or non-existent peer review, the registration of pay-to-participate 
clinical trials on public databases. It can be difficult even for professionals, let alone 
patients, to determine whether these tokens demonstrate true compliance with the 
evidentiary standards for developing and testing stem cell therapies. 
 
Misrepresentations of the safety and efficacy of stem cell interventions by commercial 
providers may build on exaggerated accounts of the state of the science in the popular 
media and research publications. Media accounts may uncritically report statements 
about the efficacy of stem cell-based treatments. Such articles are then re-posted on 
clinic websites, cited in social media, and used in crowd-funding efforts, which may 
further consolidate public expectations and arouse the curiosity of patients. However, 
the presumption of the efficacy of stem cell-based interventions is not simply a media 
issue. The pressure to publish, patent, promote, and commercialize research results, as 
well as to secure funding for future research, are all contributors to the ‘hyping’ of 
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stem cell science28.  
 
Regulatory turmoil 
National regulatory authorities have been challenged in recent decades by calls for 
faster access to medical products, even in advance of the completion of rigorous 
clinical trials. This may reduce the willingness or ability of policy makers, patient 
groups, and regulators to take a stand against the commercial promotion of unproven 
stem cell interventions. In the United States, for example, in the face of a strong push 
for deregulation by providers and patient activists, the FDA is reviewing its 
regulations on human cell and tissue products. This comes at a time when so-called 
“right to try” laws designed to weaken federal oversight of the sale of products to 
terminally ill patients have been passed in the majority of the United States29, and the 
newly enacted federal 21st Century Cures Act has included provisions for accelerating 
approvals of cell biologics30. New laws passed in Japan to stimulate the regenerative 
medicine industry through the introduction of conditional approvals (effectively 
shifting efficacy testing to a post-market context)31 have also had a major impact on 
discussions of how new stem cell-based products should be regulated.  
 Current trends toward ever greater acceleration of medical approvals are a 
cause for concern given the limits they inevitably impose on premarket testing and the 
new ethical and legal questions they raise. Whereas  medical product deregulation 
may promote access to interventions via a market model, there are accompanying 
risks to the health and economic well-being of patients. In under-regulated markets or 
those in which direct-to-consumer marketing goes unchecked, patients are obliged to 
make healthcare decisions without access to reliable information. Furthermore, 
providers may not be held accountable for the validity of their therapeutic claims, 
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thereby increasing physical, emotional and financial risks to patients and their 
families. When individuals spend their limited dollars on ineffective therapies, that 
expenditure comes at the cost of alternative effective therapies and other activities 
that could improve their quality of life; thus, patients purchasing inefficacious 
treatments might forego effective care. Further, under-regulated markets make it 
difficult for experts and non-experts to seek and evaluate information about 
competing claims. Even within regulated markets, health care is characterized by a 
high degree of information asymmetry, in which consumers must rely on providers’ 
expert knowledge. Under-regulated health markets in contrast permit a lack of reliable 
information on both sides of the equation that can be profitable to sellers without 
conferring utility to buyers. Such deficits severely limit both the opportunity for 
patients to make informed decisions and the incentives for investment in the 
development of definitive clinical evidence. Deregulation exacerbates these problems 
and thus increases the likelihood of the wasteful allocation of limited health care 
resources. 
 
Time to act 
What then is to be done? Clearly, mutual engagement across a broad range of 
stakeholders is needed to foster regulatory frameworks that facilitate progress in 
medical research and ultimately affordable clinical benefit. Uncontrolled advertising 
and delivery of stem cell interventions for which no evidence or proven rationale 
exists risks stem cell medicine becoming identified as just another instance of 
commercialization outpacing evidence. The situation is further complicated by 
jurisdictional limits on the ability to control cross-border trade in health services32. If 
the enormous public investment into stem cell research and development, and indeed 
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its real therapeutic potential, is not to be squandered, it is important that healthcare 
systems are structured in ways that incentivize scientifically grounded, clinically 
meaningful  and valuable innovation while curtailing exploitative practices.  
 
Recent history provides several examples of successful responses against direct-to-
consumer stem cell marketers. Journalistic pressure has in some cases been effective 
in exposing predatory stem cell clinics, leading to the closure of clinics in the United 
States33  and Germany13. Medical specialties, such as plastic surgery34and respiratory 
medicine35, have issued position statements highlighting the lack of sufficient 
evidence to justify routine use of stem cells in these fields, and state licensing boards 
have taken action in a small number of instances36. The Stamina Foundation incident, 
which involved dedicated efforts by biologists, physicians, social science scholars, 
lawmakers, regulators and the media over several years of often-heated public 
engagement is a case in point. Scientific experts worked with, and sometimes 
confronted, the media to get the facts straight on the actual state of the science with 
respect to the cells purportedly used by the clinic in question. This exposure was 
critical to successfully guiding the Italian government on how to handle what 
appeared to be a surge in patient demand for unproven stem cell interventions. The 
commitment of experts to public engagement also helped to foster greater public 
skepticism about therapeutic claims made by the Stamina Foundation. Several leading 
Italian scientists also made the critical decision to appeal to international colleagues to 
help them in taking a stand. After nearly five years, their advocacy efforts resulted in 
the closure of the clinic. 
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National efforts, while critically important, cannot alone succeed in countering 
the activities of a transnational industry. The effectively borderless nature of the 
internet, the ease of international travel, and jurisdictional limits on extraterritorial 
enforcement all create windows of opportunity  for clinics targeting patients across 
national borders. International research and medical organizations can play vital roles 
in supporting the work of local colleagues, but also in setting consensus regulatory 
and practice standards, driving evidence development, and facilitating the exchange 
of information among stakeholder groups. To date, organizations dedicated to stem 
cell and cell therapy research have taken the lead in global coordination, but recent 
surveys of the global stem cell marketing industry suggests that much work remains 
to be done. Proactive efforts should now be implemented by organizations with broad 
constituencies, such as the World Health Organization.   
 
We propose a cooperative model in which stakeholder groups at the national and 
international levels work together in complementary ways. Research organizations 
should advocate for appropriate regulations and accurate media representations in 
their local contexts, and may support regulatory agencies through monitoring and 
outreach efforts. The development of national guidelines that protect patients and 
human research subjects is another important role for national organizations, 
particularly in countries which have yet to formalize rules governing clinical research 
and use of human stem cell-based products. At the global level, stem cell research and 
medical organizations can support national initiatives by advising on development of 
regulations appropriate to individual nations’ specific circumstances and needs, and 
facilitating efforts to harmonize the current patchwork of national regulatory systems.  
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Setting standards is as important in science regulation as it is in scientific research, 
but regulations over the use of stem cells in medicine appear to be diversifying at the 
global level. Approaches to international regulation not only need to develop 
consistent rules over the commercialization of medical practices and products, but 
also need to give them teeth by developing cross-border partnerships for compliance 
(Figure 1). Consensus building and the inclusive consolidation of regulatory norms 
may best be facilitated by global agencies with the breadth of perspective and 
authority to coordinate and reconcile divergent interests. We note that international 
harmonization by professional, industry and other stakeholder groups has been 
broadly effective in the regulation of small-molecule drugs and biotechnologies, but 
this remains underdeveloped with respect to cellular therapeutics, which could 
similarly benefit from consensus medical practice standards, harmonization of market 
approval pathways, and resource-building for the development and enforcement of 
local regulations. In the pharmaceuticals arena, the International Council for 
Harmonization has been successful in developing and promulgating global drug 
quality standards. A similar international effort could help reduce the enormous 
heterogeneity and incompatibility of the various national systems governing stem cell 
products. For medical practice as well, the World Health Organization could 
contribute through developing guidelines on the responsible clinical use of human 
cells and tissues, and advising countries seeking to develop local practice standards. 
Importantly, the national and international elements of this model need to remain in 
communication in order to coordinate their public engagement, harmonization and 
enforcement activities. 
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However, the need for global conformity should not preclude the option of local 
action where the opportunity arises. Given the time it takes to achieve consensus on 
regulatory issues, this would allow local jurisdictions to act to protect the interests of 
their citizens, while bringing them into line with a more globally harmonized 
framework subsequently. The globalization of health markets and the specific 
tensions surrounding stem cell research and its applications have made this a difficult 
challenge. But the stakes are too high not to take a united stance. 
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Figure 1.  This scheme indicates approaches for countering the premature 
commercialization and deregulation of unproven stem cell therapies. This will 
require both local and global action by the scientific, medical and regulatory 
communities. Advocacy, monitoring, public outreach, rule-making and 
enforcement at the national level are necessary activities. These can be 
complemented by international standards-setting, coordination, engagement 
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and harmonization, which may benefit from support by authoritative 
international bodies such as the World Health Organization.  
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Table 1: Coopted tokens of scientific legitimacy  
 
Accreditations and awards Asserting certification of products or practices by international 
standards organizations, or claiming training certification. 
Boards and advisors Convening scientific or medical advisory boards featuring 
prominent business leaders and academic faculty members. 
Clinical study registration Registering trials whose apparent purpose is solely to attract 
patients willing to pay to participate in them. 
Ethics review Marketers may use the imprimatur of ‘ethics review’ to convey a 
sense of legitimacy to their products or procedures. 
Location Renting of laboratory or business space within a legitimate 
scientific or government institution. 
Membership Joining established academic or professional societies to suggest 
legitimacy by association. 
Outcome registries Publication of open-ended voluntary monitoring datasets rather 
than undertaking controlled clinical trials. 
Patenting Suggesting that patent applications or grants indicate clinical 
utility, rather than simply novelty and inventiveness. 
Publication Publishing research and commentary in journals with limited 
anonymous peer review. 
Rationales Citing preclinical and other research findings to justify clinical 
application without sufficient efficacy testing in humans. 
Self-regulation Forming organizations to ‘self-regulate’ in ways that support 
premature commercialization. 
Technical language Using scientific-sounding words that imply academic rigor. 
Testimonials and endorsements Providing glowing ‘expert’ opinions or celebrity comments on 
unsupported clinical uses or standing of the provider 
 
 
